斯派尔治疗

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4.01 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/4
• 评级变动
  LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
  \u5e02\u573a\u8d44\u8baf · 2026/9/9

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。